Fatty liver index (FLI): more than a marker of hepatic steatosis
J. physiol. biochem
; 80(1): 11-26, Feb. 2024.
Artigo
em Inglês
| IBECS
| ID: ibc-EMG-562
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Fatty liver index (FLI) was developed as a simple and accurate marker of hepatic steatosis. FLI is derived from an algorithm based on body mass index, waist circumference, and levels of triglycerides and gamma-glutamyltransferase, and it is widely used in clinical and epidemiological studies as a screening tool for discriminating between healthy and nonalcoholic fatty liver disease (NAFLD) subjects. However, a systematic review of the literature regarding FLI revealed that this index has more extensive relationships with biochemical and physiological parameters. FLI is associated with key parameters of lipid, protein and carbohydrate metabolism, hormones, vitamins and markers of inflammation, or oxidative stress. FLI can be a predictor or risk factor for a number of metabolic and nonmetabolic diseases and mortality. FLI is also used as an indicator for determining the effects of health-related prevention interventions, medications, and toxic substances on humans. Although in most cases, the exact mechanisms underlying these associations have not been fully elucidated, they are most often assumed to be mediated by insulin resistance, inflammation, and oxidative stress. Thus, FLI may be a promising marker of metabolic health due to its multiple associations with parameters of physiological and pathological processes. In this context, the present review summarizes the data from currently available literature on the associations between FLI and biochemical variables and physiological functions. We believe that this review will be of interest to researchers working in this area and can provide new perspectives and directions for future studies on FLI. (AU)
Buscar no Google
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Contexto em Saúde:
Doenças Negligenciadas
/
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Doenças Negligenciadas
/
Zoonoses
/
Doenças do Sistema Digestório
/
Doenças do Sistema Endócrino
Base de dados:
IBECS
Assunto principal:
Resistência à Insulina
/
Fatores de Risco
/
Estresse Oxidativo
/
Fígado Gorduroso
/
Inflamação
/
Pseudomonas aeruginosa
/
Bronquiectasia
/
Hemoglobinas
/
Apresentação de Dados
/
Ciprofloxacina
Tipo de estudo:
Estudo diagnóstico
/
Estudo de etiologia
/
Estudo observacional
/
Estudo de prevalência
/
Estudo prognóstico
/
Fatores de risco
Limite:
Humanos
/
Feminino
/
Lactente
/
Masculino
País/Região como assunto:
México
Idioma:
Espanhol
/
Inglês
Revista:
J. physiol. biochem
/
An. pediatr. (2003. Ed. impr.)
/
Arch. bronconeumol. (Ed. impr.)
/
Cir. Esp. (Ed. impr.)
/
Nutr. hosp
/
Rev. esp. patol. torac
Ano de publicação:
2023
/
2022
/
2024
Tipo de documento:
Artigo
Instituição/País de afiliação:
Russian Academy of Sciences/Russia
/
Charité Universitätsmedizin Berlin/Germany
/
Deutsche Sporthochschule Köln/Germany
/
Escuela de Medicina y Ciencias de la Salud/México
/
Hospital Infantil Universitario Niño Jesús/España
/
Hospital Juárez de México/México
/
Hospital Regional de Alta Especialidad de la Península de Yucatán/México
/
Hospital Universitario La Paz/España
/
Hospital universitario Jerez de la Frontera/España
/
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán/México